A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Summary

This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Timeline

Start

2023-06-13

Primary completion

2026-12-01

Completion

2026-12-31

Drugs

Indications